Eyeworld

IQ Vivity™ Toric IOLs and are indicated for primary implantation for the visual correction of aphakia in adult patients with <1.00 D of preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the eff ects of presbyopia by providing an extended depth of focus. Compared to an aspheric IQ Vivity™ IOL is intended for capsular bag placement only. In addition, the AcrySof ® IQ Vivity™ IOL is intended for capsular bag placement only. In addition, the AcrySof ® IQ Vivity™ IOL is intended for capsular bag placement only. In addition, the AcrySof Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefi t ratio before implanting a lens in a patient with any of the conditions described This lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should IQ Vivity™ IOL are likely to experience signifi cant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffi c. It is possible to experience very bothersome visual disturbances, IQ Vivity™ IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefi ts associated with AcrySof ® AcrySof ® AcrySof IQ Vivity™ Family of Extended Vision IOLs IQ Vivity™ Family of Extended Vision IOLs IMPORTANT PRODUCT INFORMATION IMPORTANT PRODUCT INFORMATION CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof The AcrySof ® The AcrySof ® The AcrySof IQ Vivity™ Extended Vision IOLs include AcrySof ® IQ Vivity™ Extended Vision IOLs include AcrySof ® IQ Vivity™ Extended Vision IOLs include AcrySof IQ Vivity™ and AcrySof ® IQ Vivity™ and AcrySof ® IQ Vivity™ and AcrySof IQ Vivity™ Toric IOLs and are indicated for primary implantation for the visual correction of aphakia in adult patients with <1.00 D of preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the eff ects of presbyopia by providing an extended depth of focus. Compared to an aspheric preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the eff ects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof ® monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof ® monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof IQ Vivity™ IOL is intended for capsular bag placement only. In addition, the AcrySof IQ Vivity™ Toric IOL is indicated for the reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism. IQ Vivity™ Toric IOL is indicated for the reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism. WARNINGS/PRECAUTIONS: WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefi t ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. in the Directions for Use labeling. This lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should This lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should occur as early as possible prior to lens encapsulation. Most patients implanted with the AcrySof occur as early as possible prior to lens encapsulation. Most patients implanted with the AcrySof ® occur as early as possible prior to lens encapsulation. Most patients implanted with the AcrySof ® occur as early as possible prior to lens encapsulation. Most patients implanted with the AcrySof IQ Vivity™ IOL are likely to experience signifi cant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof ® that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof ® that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof ® that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffi c. It is possible to experience very bothersome visual disturbances, signifi cant enough that the patient could request explant of the IOL. In the AcrySof ® signifi cant enough that the patient could request explant of the IOL. In the AcrySof ® signifi cant enough that the patient could request explant of the IOL. In the AcrySof IQ Vivity™ IOL clinical study, 1% to 2% of AcrySof ® IQ Vivity™ IOL clinical study, 1% to 2% of AcrySof ® IQ Vivity™ IOL clinical study, 1% to 2% of AcrySof IQ Vivity™ IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefi ts associated with the AcrySof ® the AcrySof ® the AcrySof IQ Vivity™ IOLs. ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings, and precautions. © 2020 Alcon Inc. 12/20 US-VIV-2000097 V I V I T Y V I E W EMBRACE THE EMBRACE THE Expand visual possibilities with the AcrySof ® IQ Vivity ™ IOL, the fi rst and only non-diff ractive extended depth of focus IOL. Learn more about the AcrySof ® IQ Vivity ™ IOL today at: VivityView.com.

• Blank Page
• Blank Page (1)